MCZ, SNGX, PVCT are included in our Top Penny Stock Gainers
Mad Catz Interactive,
Inc. (AMEX/TSX: MCZ)
reached up 26.62% in morning trading to $.81 with 1.5M shares traded. Mad Catz
Interactive, Inc. is a global provider of innovative interactive entertainment
products marketed primarily under its Mad Catz® (casual gaming), Cyborg™ (pro
gaming), Tritton® (gaming audio), Saitek® (simulation), and Eclipse™ (home and
office) brands. Mad Catz also develops flight simulation software through its
internal ThunderHawk Studios™; operates flight simulation centers under its
Saitek brand; operates a videogame content website under its GameShark® brand;
publishes games under its Mad Catz brand; and distributes games and videogame
products for third parties. Mad Catz distributes its products through most
leading retailers offering interactive entertainment products and has offices
in North America, Europe and Asia. Mad Catz Interactive, Inc. (AMEX/TSX: MCZ)
announced today that it has entered into a PlayStation® Accessory Licensing
Agreement with SCEJ (Sony Computer Entertainment Japan), a division of Sony
Computer Entertainment Inc.
Soligenix, Inc. (OTCBB: SNGX) reached up 32.14% in
morning trading to $.037 with 1M shares traded. Soligenix is a development
stage biopharmaceutical company developing products to treat life-threatening
side effects of cancer treatments and serious gastrointestinal diseases, and
vaccines for certain bioterrorism agents. Soligenix's lead product, orBec®
(oral beclomethasone dipropionate), is a potent, locally acting corticosteroid
that has been initially developed for the treatment of acute gastrointestinal
Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening
complication of hematopoietic cell transplantation. Soligenix is also
conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial
of SGX201 in the prevention of acute radiation enteritis. Additionally,
Soligenix is developing SGX203 for the treatment of pediatric Crohn's disease.
Soligenix, Inc. (OTCBB: SNGX) announced today results from long-term stability
studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA
(recombinant protective antigen) subunit protein vaccine, known as SGX204.
Provectus
Pharmaceuticals, Inc. (OTCBB: PVCT) reached up 13.48% in morning trading to
$1.01 with 200K shares traded. Provectus Pharmaceuticals specializes in
developing oncology and dermatology therapies. Its novel oncology drug PV-10 is
designed to selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side effects. Its
oncology focus is on melanoma, breast cancer and cancers of the liver. The
Company has received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. Its dermatological drug PH-10 also
targets abnormal or diseased cells, with the current focus on psoriasis and
atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as
a therapy for metastatic melanoma, and of PH-10 as a topical treatment for
atopic dermatitis and psoriasis. Provectus Pharmaceuticals, Inc. (OTCBB: PVCT)
announced today they have received guidance from the U.S. Food and Drug
Administration ("FDA") to submit its Phase 3 protocol for review,
either via standard review or a request for Special Protocol Assessment
(“SPA”).
For a detailed quote
on any of the following companies, or to read the full news articles visit PennyTrader.com
About
PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to
covering the microcap market space including Pink Sheets and OTC Bulletin Board
and sub-$5 big board stocks. We strive to provide you with the best stocks
alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board
stocks, and timely stocks picks and alerts. Our goal is to inform you of the
HOTTEST stocks in the market before they move. Our staff has years experience
in the stock market, and we are confident that you’ll be impressed with the
results of our stock picks! If you wish to feature your organization on our
website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being
compensated for any stocks covered in
this midday report
PennyTrader.com is not a registered investment advisers or
broker/dealer. PennyTrader.com makes no recommendation that the purchase of
securities of companies profiled in this press release is suitable or advisable
for any person or that an investment such securities will be profitable. In
general, given the nature of the micro cap companies covered and the potential
lack of an active trading market their securities, investing in such securities
is highly speculative and carries a high degree of risk. For our full
disclaimer go to CLICK
HERE
